ReviewNanotechnology, science and applications2015
Nanotechnology-based inhalation treatments for lung cancer: state of the art.
Review in Nanotechnology, science and applications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 169 citations in OpenAlex.
- A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy.Cancer medicine · 2026Article
- Navigating toxicity in lung cancer immunotherapy: challenges and advances in Nano medicine drug delivery.Journal of the Egyptian National Cancer Institute · 2026Review
- Improving the bioavailability of nintedanib by formulating inhalable ufasomes as a targeted therapy for non-small cell lung cancer.International journal of pharmaceutics: X · 2026Article
- Predictive Screening of TaACS nano · 2026Article
- Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- Silk protein discoidal microparticles for site-specific delivery of docetaxel in metastatic lung cancer.Materials today. Bio · 2025Article
- Nano-formulations in disease therapy: designs, advances, challenges, and future directions.Journal of nanobiotechnology · 2025Review
- Enhancing Lung Recovery: Inhaled Poly(lactic-ACS nano · 2025Article
- Transforming Lung Cancer Care: The Role of Transferosomes in Modern Drug Delivery.Current cancer drug targets · 2025Review
- Ferulic Acid: A Comprehensive Review.Cureus · 2024Review
- Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets.Annual review of biomedical engineering · 2024Review
- Drug-loaded polymer-coated silver nanoparticles for lung cancer theranostics.Medical oncology (Northwood, London, England) · 2024Article
- Pulmonary inhalation for disease treatment: Basic research and clinical translations.Materials today. Bio · 2024Review
- Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives.Pharmaceutics · 2024Review
- Cisplatin-based Liposomal Nanocarriers for Drug Delivery in Lung Cancer Therapy: Recent Progress and Future Outlooks.Current pharmaceutical design · 2024Review
- Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.Current pharmaceutical biotechnology · 2024Review
- Recent Updates in Inhalable Drug Delivery System against Various Pulmonary Diseases: Challenges and Future Perspectives.Current drug delivery · 2024Review
- Review
- Nano vs Resistant Tuberculosis: Taking the Lung Route.AAPS PharmSciTech · 2023Review
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the challenges associated with conventional chemotherapy, targeted and local delivery of chemotherapeutics via nanoparticle (NP) carriers to the lungs is an emerging area of interest. Recent studies and growing clinical application in cancer nanotechnology showed the huge potential of NPs as drug carriers in cancer therapy, including in lung carcinoma for diagnosis, imaging, and theranostics. Researchers have confirmed that nanotechnology-based inhalation chemotherapy is viable and more effective than conventional chemotherapy, with lesser side effects. Recently, many nanocarriers have been investigated, including liposomes, polymeric micelles, polymeric NPs, solid lipid NPs, and inorganic NPs for inhalation treatments of lung cancer. Yet, the toxicity of such nanomaterials to the lungs tissues and further distribution to other organs due to systemic absorption on inhalation delivery is a debatable concern. Here, prospect of NPs-based local lung cancer targeting through inhalation route as well as its associated challenges are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.